Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Allogene Therapeutics: Q3 Earnings Snapshot

11/04/2021 | 03:25pm EST

SOUTH SAN FRANCISCO, Calif. (AP) _ Allogene Therapeutics Inc. (ALLO) on Thursday reported a loss of $78.2 million in its third quarter.

The South San Francisco, California-based company said it had a loss of 57 cents per share.

The results fell short of Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for a loss of 56 cents per share.

The immuno-oncology company posted revenue of $49,000 in the period.

Allogene Therapeutics shares have fallen 23% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $19.43, a fall of 37% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALLO at https://www.zacks.com/ap/ALLO

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about ALLOGENE THERAPEUTICS, INC.
01/18Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical H..
AQ
01/14INSIDER BUY : Allogene Therapeutics
MT
01/12Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement wi..
AQ
01/11ALLOGENE THERAPEUTICS : JPM Presentation 2022
PU
01/11Allogene Therapeutics Enters Into Cancer Therapy Collaboration With Antion Biosciences
MT
01/11Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T Clini..
AQ
01/11Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement wi..
AQ
01/11Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical ..
AQ
01/11US FDA Lifts Hold on Cellectis Partner's Clinical Studies of Cancer Therapy
MT
01/11Antion Biosciences SA announced that it expects to receive funding from Allogene Therap..
CI
More news
Analyst Recommendations on ALLOGENE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 38,4 M - -
Net income 2021 -265 M - -
Net cash 2021 492 M - -
P/E ratio 2021 -5,77x
Yield 2021 -
Capitalization 1 616 M 1 616 M -
EV / Sales 2021 29,3x
EV / Sales 2022 444x
Nbr of Employees 301
Free-Float -
Chart ALLOGENE THERAPEUTICS, INC.
Duration : Period :
Allogene Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLOGENE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 11,34 $
Average target price 32,38 $
Spread / Average Target 185%
EPS Revisions
Managers and Directors
David D. Chang President, Chief Executive Officer & Director
Eric Schmidt Chief Financial Officer
Arie S. Belldegrun Executive Chairman
Alison Moore Chief Technical Officer
Barbra Sasu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ALLOGENE THERAPEUTICS, INC.-23.99%1 619
GILEAD SCIENCES, INC.-5.65%85 938
REGENERON PHARMACEUTICALS-1.60%64 971
VERTEX PHARMACEUTICALS3.86%57 990
WUXI APPTEC CO., LTD.-5.63%49 645
BIONTECH SE-42.79%35 624